226 related articles for article (PubMed ID: 25712859)
1. Ablating N-acetylaspartate prevents leukodystrophy in a Canavan disease model.
Guo F; Bannerman P; Mills Ko E; Miers L; Xu J; Burns T; Li S; Freeman E; McDonough JA; Pleasure D
Ann Neurol; 2015 May; 77(5):884-8. PubMed ID: 25712859
[TBL] [Abstract][Full Text] [Related]
2. Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy.
Sohn J; Bannerman P; Guo F; Burns T; Miers L; Croteau C; Singhal NK; McDonough JA; Pleasure D
J Neurosci; 2017 Jan; 37(2):413-421. PubMed ID: 28077719
[TBL] [Abstract][Full Text] [Related]
3. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.
von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M
Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375
[TBL] [Abstract][Full Text] [Related]
4. Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model.
Bannerman P; Guo F; Chechneva O; Burns T; Zhu X; Wang Y; Kim B; Singhal NK; McDonough JA; Pleasure D
Mol Ther; 2018 Mar; 26(3):793-800. PubMed ID: 29456021
[TBL] [Abstract][Full Text] [Related]
5. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time.
Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M
J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242
[TBL] [Abstract][Full Text] [Related]
6. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.
Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P
Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881
[TBL] [Abstract][Full Text] [Related]
7. Canavan disease and the role of N-acetylaspartate in myelin synthesis.
Namboodiri AM; Peethambaran A; Mathew R; Sambhu PA; Hershfield J; Moffett JR; Madhavarao CN
Mol Cell Endocrinol; 2006 Jun; 252(1-2):216-23. PubMed ID: 16647192
[TBL] [Abstract][Full Text] [Related]
8. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology.
Moffett JR; Ross B; Arun P; Madhavarao CN; Namboodiri AM
Prog Neurobiol; 2007 Feb; 81(2):89-131. PubMed ID: 17275978
[TBL] [Abstract][Full Text] [Related]
9. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ
Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013
[TBL] [Abstract][Full Text] [Related]
10. Ablating the Transporter Sodium-Dependent Dicarboxylate Transporter 3 Prevents Leukodystrophy in Canavan Disease Mice.
Wang Y; Hull V; Sternbach S; Popovich B; Burns T; McDonough J; Guo F; Pleasure D
Ann Neurol; 2021 Nov; 90(5):845-850. PubMed ID: 34498299
[TBL] [Abstract][Full Text] [Related]
11. NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model.
Becker I; Wang-Eckhardt L; Eckhardt M
J Inherit Metab Dis; 2024 Mar; 47(2):230-243. PubMed ID: 38011891
[TBL] [Abstract][Full Text] [Related]
12. Canavan's spongiform leukodystrophy: a clinical anatomy of a genetic metabolic CNS disease.
Baslow MH
J Mol Neurosci; 2000 Oct; 15(2):61-9. PubMed ID: 11220786
[TBL] [Abstract][Full Text] [Related]
13. Pathophysiology and Treatment of Canavan Disease.
Pleasure D; Guo F; Chechneva O; Bannerman P; McDonough J; Burns T; Wang Y; Hull V
Neurochem Res; 2020 Mar; 45(3):561-565. PubMed ID: 30535831
[No Abstract] [Full Text] [Related]
14. Redirecting
Gessler DJ; Li D; Xu H; Su Q; Sanmiguel J; Tuncer S; Moore C; King J; Matalon R; Gao G
JCI Insight; 2017 Feb; 2(3):e90807. PubMed ID: 28194442
[TBL] [Abstract][Full Text] [Related]
15. Pathological Bergmann glia alterations and disrupted calcium dynamics in ataxic Canavan disease mice.
Hull VL; Wang Y; Burns T; Sternbach S; Gong S; McDonough J; Guo F; Borodinsky LN; Pleasure D
Glia; 2023 Dec; 71(12):2832-2849. PubMed ID: 37610133
[TBL] [Abstract][Full Text] [Related]
16. Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease.
Madhavarao CN; Arun P; Moffett JR; Szucs S; Surendran S; Matalon R; Garbern J; Hristova D; Johnson A; Jiang W; Namboodiri MA
Proc Natl Acad Sci U S A; 2005 Apr; 102(14):5221-6. PubMed ID: 15784740
[TBL] [Abstract][Full Text] [Related]
17. Astroglial conditional Slc13a3 knockout is therapeutic in murine Canavan leukodystrophy.
Hull VL; Wang Y; McDonough J; Zhu M; Burns T; Al Ramel N; Dehghani A; Guo F; Pleasure D
Ann Clin Transl Neurol; 2024 Apr; 11(4):1059-1062. PubMed ID: 38282243
[TBL] [Abstract][Full Text] [Related]
18. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.
Traka M; Wollmann RL; Cerda SR; Dugas J; Barres BA; Popko B
J Neurosci; 2008 Nov; 28(45):11537-49. PubMed ID: 18987190
[TBL] [Abstract][Full Text] [Related]
19. The effects of lithium chloride and other substances on levels of brain N-acetyl-L-aspartic acid in Canavan disease-like rats.
Baslow MH; Kitada K; Suckow RF; Hungund BL; Serikawa T
Neurochem Res; 2002 May; 27(5):403-6. PubMed ID: 12064356
[TBL] [Abstract][Full Text] [Related]
20. Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease?
Baslow MH; Guilfoyle DN
Neurochem Res; 2009 Sep; 34(9):1523-34. PubMed ID: 19319678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
